Home/Pipeline/Crofelemer (Animal Health)

Crofelemer (Animal Health)

Chemotherapy-Induced Diarrhea in dogs

PreclinicalDevelopment

Key Facts

Indication
Chemotherapy-Induced Diarrhea in dogs
Phase
Preclinical
Status
Development
Company

About Jaguar Health

Jaguar Health is a commercial-stage biopharmaceutical company with a mission to develop and commercialize novel, plant-based prescription medicines for gastrointestinal conditions. Its core asset is Mytesi (crofelemer), the first and only FDA-approved anti-secretory agent for HIV/AIDS-related diarrhea, derived sustainably from the Croton lechleri tree. The company is leveraging its expertise in botanical drug development to expand crofelemer's indications into cancer therapy-related diarrhea and other areas of significant unmet need, while also exploring its potential in veterinary medicine through its subsidiary, Napo Therapeutics.

View full company profile

About Jaguar Health

Jaguar Health is a commercial-stage biopharmaceutical company with a mission to develop and commercialize novel, plant-based prescription medicines for gastrointestinal conditions. Its core asset is Mytesi (crofelemer), the first and only FDA-approved anti-secretory agent for HIV/AIDS-related diarrhea, derived sustainably from the Croton lechleri tree. The company is leveraging its expertise in botanical drug development to expand crofelemer's indications into cancer therapy-related diarrhea and other areas of significant unmet need, while also exploring its potential in veterinary medicine through its subsidiary, Napo Therapeutics.

View full company profile